Headline
The latest stories from AHA Today.
The Centers for Medicare & Medicaid Services announced Medicare coverage for monoclonal antibody therapies, with no beneficiary cost-sharing for the duration of the COVID-19 public health emergency. CMS said the coverage will apply to bamlanivimab, the Lilly therapeutic that earned an emergency…
A U.S. district court judge Nov. 3 ordered United Behavioral Health, part of UnitedHealth Group, to reprocess close to 67,000 mental health and substance use disorder benefit claims denied over a six-year period.
The Drug Enforcement Administration published an interim final rule expanding access to medication-assisted treatment under the SUPPORT for Patients and Communities Act of 2018.
The Senate Committee on Appropriations released all 12 of its fiscal year 2021 funding measures, including the appropriations bill for the departments of Labor, Health and Human Services, Education and related agencies.
The U.S. Supreme Court heard oral argument in the latest challenge to the Affordable Care Act.
David Zaas, M.D., chief clinical officer for MUSC Health in South Carolina and CEO of its Charleston Division, talks with Nancy Foster, AHA vice president for quality and patient safety, about strategies and tools to address burnout as health care professionals continue to care for COVID-19…
A new report from the National Academies of Sciences, Engineering, and Medicine examines the advantages, limitations and status of certain COVID-19 diagnostic tests, including reverse transcription polymerase chain reaction tests, point-of-care tests, and next generation sequencing tests.
ECRI tested 34 disposable isolation gown models made by foreign or non-traditional suppliers and found that about half did not meet the minimum U.S. standard for liquid barrier protection, the organization said in a report released.
The Department of Veterans Affairs released an interim final rule clarifying that VA nurses and other health care professionals can deliver health care services in a state other than their state of licensure, registration, certification or other requirement.
The Food and Drug Administration Nov. 10 issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy, bamlanivimab.